Figure 3.
Th1 and Th2, but not Th17; CD4 T subsets are affected by treatment with omalizumab. Percentages of (A) central memory Th1 (B) central memory Th2, (C) central memory Th17, (D) effector memory Th1, (E) effector memory Th2, and (F) effector memory Th17 T cells in peripheral blood of HD, NID, and CSU patients under omalizumab treatment. CSU, chronic spontaneous urticaria; HD, healthy donors (n = 50); NID, non-immunomodulatory drugs (n = 27); OZB, omalizumab (n = 24).
